astemizole has been researched along with Torsade de Pointes in 28 studies
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.
astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since astemizole in an oral dose of 50 mg/kg/day was recently reported to exert anti-cancer effect in mice, we evaluated its proarrhythmic potential using the atrioventricular block dogs in order to clarify its cardiac safety profile." | 7.83 | Possibility as an anti-cancer drug of astemizole: Evaluation of arrhythmogenicity by the chronic atrioventricular block canine model. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2016) |
| " In order to study the effects of anesthetic agents on the inducibility of TdP, arrhythmias were induced by programmed electrical stimulation (PES) before and after cumulative intravenous administration of quinidine under anesthesia with sodium pentobarbital, halothane, or isoflurane." | 7.71 | Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. ( Imai, R; Tamura, T; Yamamoto, K; Yamamoto, M, 2001) |
| "QT interval prolongation and torsade de pointes are associated with astemizole intake and have been ascribed to block the repolarizing K+ currents, specifically the rapidly activating component of the delayed rectifier iKr." | 7.69 | Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. ( Hoon, TJ; January, CT; Mohammad, S; Studenik, C; Vorperian, VR; Zhou, Z, 1996) |
| "Prolongation of the QT interval and torsade de pointes has been reported in patients with an overdose of astemizole." | 5.30 | Combined use of astemizole and ketoconazole resulting in torsade de pointes. ( Chen, JH; Tsai, LM; Tsai, WC, 1997) |
| "The possible occurrence of torsade de pointes in astemizole overdose, and the long elimination time of astemizole and hydroxylated metabolites, makes it necessary to maintain ECG monitoring until QT interval has returned to normal." | 5.29 | Prolonged QT interval and torsade de pointes following astemizole overdose. ( Danel, V; Dixmerias, F; Saviuc, P, 1993) |
| "Astemizole (Hismanal-Janssen, New Brunswick, NJ) is a nonsedating antihistamine that has the advantage of a once-daily dosage schedule." | 5.29 | Torsade de pointes associated with Astemizole overdose treated with magnesium sulfate. ( Hasan, RA; Nolan, BM; Zureikat, GY, 1993) |
| "Since astemizole in an oral dose of 50 mg/kg/day was recently reported to exert anti-cancer effect in mice, we evaluated its proarrhythmic potential using the atrioventricular block dogs in order to clarify its cardiac safety profile." | 3.83 | Possibility as an anti-cancer drug of astemizole: Evaluation of arrhythmogenicity by the chronic atrioventricular block canine model. ( Ando, K; Cao, X; Izumi-Nakaseko, H; Nakamura, Y; Sugiyama, A; Wada, T, 2016) |
| " In order to study the effects of anesthetic agents on the inducibility of TdP, arrhythmias were induced by programmed electrical stimulation (PES) before and after cumulative intravenous administration of quinidine under anesthesia with sodium pentobarbital, halothane, or isoflurane." | 3.71 | Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. ( Imai, R; Tamura, T; Yamamoto, K; Yamamoto, M, 2001) |
| "Astemizole is a potent histamine H1-antagonist that has been associated with cases of life-threatening cardiac arrhythmias, including torsade de pointes and atrioventricular (AV) block." | 3.69 | Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. ( Adamantidis, MM; Caron, JF; Dupuis, BA; Lacroix, DL, 1995) |
| "QT interval prolongation and torsade de pointes are associated with astemizole intake and have been ascribed to block the repolarizing K+ currents, specifically the rapidly activating component of the delayed rectifier iKr." | 3.69 | Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. ( Hoon, TJ; January, CT; Mohammad, S; Studenik, C; Vorperian, VR; Zhou, Z, 1996) |
| "Ebastine also inhibit potassium channels, cloned human Kv 1." | 2.41 | [The effect of second generation histamine antagonists on the heart]. ( Górska, M; Grzelewska-Rzymowska, I; Pietrzkowicz, M, 2001) |
| " This paper reviews the pharmacokinetic properties of these second-generation agents and is intended to provide comparisons that help explain differences in dosing profiles and drug interactions for members of this class of drugs." | 2.40 | Pharmacokinetic overview of oral second-generation H1 antihistamines. ( Estes, KS; González, MA, 1998) |
| " The primary difference between traditional (first-generation) and nonsedating (second-generation) histamine1-receptor antagonists is the incidence and severity of adverse reactions." | 2.39 | Cardiovascular toxicity of antihistamines. ( Smith, SJ, 1994) |
| "Treatment of astemizole-induced torsades de pointes includes discontinuing use of astemizole, intravenous administration of magnesium sulfate and isoproterenol, temporary cardiac pacing, and, when necessary, direct current cardioversion." | 2.39 | Torsades de pointes ventricular tachycardia associated with overdose of astemizole. ( Adlakha, A; Meloy, TD; Rao, KA; Stanton, MS; Verma-Ansil, B, 1994) |
| " The lessons learned from the experiences with these drugs hold implications for the future development of agents that prolong the QT interval and suggest the need for dose-response relation data and metabolic evaluations to define the subpopulations at particular risk." | 1.29 | Is QT interval prolongation harmful? A regulatory perspective. ( Botstein, P, 1993) |
| "The possible occurrence of torsade de pointes in astemizole overdose, and the long elimination time of astemizole and hydroxylated metabolites, makes it necessary to maintain ECG monitoring until QT interval has returned to normal." | 1.29 | Prolonged QT interval and torsade de pointes following astemizole overdose. ( Danel, V; Dixmerias, F; Saviuc, P, 1993) |
| "Astemizole (Hismanal-Janssen, New Brunswick, NJ) is a nonsedating antihistamine that has the advantage of a once-daily dosage schedule." | 1.29 | Torsade de pointes associated with Astemizole overdose treated with magnesium sulfate. ( Hasan, RA; Nolan, BM; Zureikat, GY, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (67.86) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 2 (7.14) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Pearlstein, R | 1 |
| Vaz, R | 1 |
| Rampe, D | 1 |
| Kramer, J | 1 |
| Obejero-Paz, CA | 1 |
| Myatt, G | 1 |
| Kuryshev, YA | 1 |
| Bruening-Wright, A | 1 |
| Verducci, JS | 1 |
| Brown, AM | 1 |
| Goto, A | 1 |
| Sakamoto, K | 1 |
| Kambayashi, R | 1 |
| Izumi-Nakaseko, H | 2 |
| Kawai, S | 1 |
| Takei, Y | 1 |
| Matsumoto, A | 1 |
| Kanda, Y | 1 |
| Sugiyama, A | 2 |
| Nakamura, Y | 1 |
| Cao, X | 1 |
| Wada, T | 1 |
| Ando, K | 1 |
| Dabhi, J | 1 |
| Mehta, A | 1 |
| Adamantidis, MM | 1 |
| Lacroix, DL | 1 |
| Caron, JF | 1 |
| Dupuis, BA | 1 |
| Kelloway, JS | 1 |
| Pongowski, MA | 1 |
| Schoenwetter, WF | 1 |
| Smith, SJ | 1 |
| Rao, KA | 1 |
| Adlakha, A | 1 |
| Verma-Ansil, B | 1 |
| Meloy, TD | 1 |
| Stanton, MS | 1 |
| Wiley, JF | 1 |
| Henretig, FM | 1 |
| Goss, JE | 1 |
| Ramo, BW | 1 |
| Blake, K | 1 |
| Botstein, P | 1 |
| Herings, RM | 1 |
| Stricker, BH | 1 |
| Leufkens, HG | 1 |
| Bakker, A | 1 |
| Sturmans, F | 1 |
| Urquhart, J | 1 |
| Saviuc, P | 1 |
| Danel, V | 1 |
| Dixmerias, F | 1 |
| Sakemi, H | 1 |
| VanNatta, B | 1 |
| Hasan, RA | 1 |
| Zureikat, GY | 1 |
| Nolan, BM | 1 |
| Woosley, RL | 1 |
| Hsieh, MH | 1 |
| Chen, SA | 1 |
| Chiang, CE | 1 |
| Tai, CT | 1 |
| Lee, SH | 1 |
| Wen, ZC | 1 |
| Chang, MS | 1 |
| Vorperian, VR | 1 |
| Zhou, Z | 1 |
| Mohammad, S | 1 |
| Hoon, TJ | 1 |
| Studenik, C | 1 |
| January, CT | 1 |
| Tsai, WC | 1 |
| Tsai, LM | 1 |
| Chen, JH | 1 |
| Martin, ES | 1 |
| Rogalski, K | 1 |
| Black, JN | 1 |
| Ikeda, S | 1 |
| Oka, H | 1 |
| Matunaga, K | 1 |
| Kubo, S | 1 |
| Asai, S | 1 |
| Miyahara, Y | 1 |
| Osaka, A | 1 |
| Kohno, S | 1 |
| González, MA | 1 |
| Estes, KS | 1 |
| DuBuske, LM | 1 |
| Gilbert, JD | 1 |
| Cahill, SA | 1 |
| McCartney, DG | 1 |
| Lukas, A | 1 |
| Gross, GJ | 1 |
| Yamamoto, K | 1 |
| Tamura, T | 1 |
| Imai, R | 1 |
| Yamamoto, M | 1 |
| Mansfield, RJ | 1 |
| Thomas, RD | 1 |
| Grzelewska-Rzymowska, I | 1 |
| Pietrzkowicz, M | 1 |
| Górska, M | 1 |
7 reviews available for astemizole and Torsade de Pointes
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ER | 2003 |
Cardiovascular toxicity of antihistamines.
Topics: Astemizole; Drug Interactions; Heart; Histamine H1 Antagonists; Humans; Terfenadine; Torsades de Poi | 1994 |
Torsades de pointes ventricular tachycardia associated with overdose of astemizole.
Topics: Adult; Astemizole; Drug Overdose; Electrocardiography; Female; Humans; Rhinitis, Vasomotor; Torsades | 1994 |
Cardiac actions of antihistamines.
Topics: Animals; Astemizole; Cetirizine; Diphenhydramine; Drug Interactions; Histamine H1 Antagonists; Human | 1996 |
Pharmacokinetic overview of oral second-generation H1 antihistamines.
Topics: Astemizole; Blood-Brain Barrier; Cetirizine; Histamine H1 Antagonists; Humans; Loratadine; Structure | 1998 |
Second-generation antihistamines: the risk of ventricular arrhythmias.
Topics: Animals; Astemizole; Cytochrome P-450 Enzyme System; Drug Interactions; Electrocardiography; Heart; | 1999 |
[The effect of second generation histamine antagonists on the heart].
Topics: Animals; Area Under Curve; Astemizole; Butyrophenones; Electrocardiography; Heart; Histamine H1 Anta | 2001 |
21 other studies available for astemizole and Torsade de Pointes
| Article | Year |
|---|---|
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp T | 2013 |
Validation of Risk-Stratification Method for the Chronic Atrioventricular Block Cynomolgus Monkey Model and Its Mechanistic Interpretation Using 6 Drugs With Pharmacologically Distinct Profile.
Topics: Animals; Astemizole; Atrioventricular Block; DNA-Binding Proteins; Electrocardiography; Haloperidol; | 2022 |
Possibility as an anti-cancer drug of astemizole: Evaluation of arrhythmogenicity by the chronic atrioventricular block canine model.
Topics: Animals; Antineoplastic Agents; Astemizole; Atrioventricular Block; Disease Models, Animal; Dogs; Fe | 2016 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electroc | 2007 |
Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Astemizole; Dose-Response Relationship, Drug; Hist | 1995 |
Additional causes of torsades de pointes.
Topics: Astemizole; Drug Overdose; Humans; Terfenadine; Torsades de Pointes | 1995 |
Torsade de pointes.
Topics: Adolescent; Astemizole; Drug Overdose; Humans; Magnesium Sulfate; Torsades de Pointes | 1993 |
Torsades de pointes associated with astemizole (Hismanal) therapy.
Topics: Aged; Aged, 80 and over; Astemizole; Erythromycin; Female; Humans; Hypokalemia; Torsades de Pointes | 1993 |
Is QT interval prolongation harmful? A regulatory perspective.
Topics: Astemizole; Butylamines; Electrocardiography; Humans; Terfenadine; Torsades de Pointes; Urinary Inco | 1993 |
Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Astemizole; Child; Child, Preschool; Drug Synergism; Dru | 1993 |
Prolonged QT interval and torsade de pointes following astemizole overdose.
Topics: Adult; Astemizole; Drug Overdose; Electrocardiography; Female; Gastric Lavage; Half-Life; Humans; Is | 1993 |
Torsade de pointes induced by astemizole in a patient with prolongation of the QT interval.
Topics: Adult; Astemizole; Electrocardiography; Female; Humans; Long QT Syndrome; Torsades de Pointes | 1993 |
Torsade de pointes associated with Astemizole overdose treated with magnesium sulfate.
Topics: Adolescent; Astemizole; Drug Overdose; Electrocardiography; Female; Humans; Magnesium Sulfate; Poiso | 1993 |
Drug-induced torsades de pointes in one patient with congenital long QT syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Astemizole; Cardiac Pacing, Artificial; Electr | 1996 |
Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole.
Topics: Aged; Aged, 80 and over; Animals; Astemizole; Electrocardiography; Female; Heart; Heart Arrest; Hist | 1996 |
Combined use of astemizole and ketoconazole resulting in torsade de pointes.
Topics: Antifungal Agents; Astemizole; Drug Interactions; Electrocardiography; Female; Histamine H1 Antagoni | 1997 |
Quinine may trigger torsades de pointes during astemizole therapy.
Topics: Adult; Anti-Allergic Agents; Astemizole; Drug Interactions; Drug Therapy, Combination; Female; Hista | 1997 |
Astemizole-induced torsades de pointes in a patient with vasospastic angina.
Topics: Aged; Angina Pectoris, Variant; Anti-Allergic Agents; Astemizole; Coronary Vasospasm; Female; Humans | 1998 |
Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Astemizole; Cetirizine; Electrocardiography; Heart | 2000 |
Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole.
Topics: Acute Disease; Anesthesia; Anesthetics, Inhalation; Animals; Astemizole; Atrioventricular Node; Cath | 2001 |
Recurrent syncope. Drug induced long QT syndrome.
Topics: Adult; Anti-Allergic Agents; Antimalarials; Astemizole; Chloroquine; Electrocardiography; Humans; Lo | 2001 |